Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Spending More Won’t Necessarily Improve Acute MI Outcomes

Todd Neale

December 22, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Daily News

EVAR Shown to IMPROVE Outcomes Over Surgery for Ruptured AAA Patients

L.A. McKeown

November 17, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

Todd Neale

November 11, 2017

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

Presentation TCT 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, William F. Fearon

November 02, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

News Conference News TCT 2017

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

Yael L. Maxwell

October 31, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Female Surgeons Hold Slight Edge Over Male Peers in Terms of Patients’ 30-Day Mortality

Caitlin E. Cox

October 11, 2017

News Daily News

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

L.A. McKeown

October 09, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Opinion Fellow Talk

Cost Awareness and Fellowship Education

Amit K. Gupta, MBBS, MD

August 31, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Advertisement

Spending More Won’t Necessarily Improve Acute MI Outcomes

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

EVAR Shown to IMPROVE Outcomes Over Surgery for Ruptured AAA Patients

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Female Surgeons Hold Slight Edge Over Male Peers in Terms of Patients’ 30-Day Mortality

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Cost Awareness and Fellowship Education

Evolocumab Not Cost-Effective at Current List Price

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content